Status:
UNKNOWN
Concurent Chemoradiotherapy in Head and Neck Cancers
Lead Sponsor:
Assiut University
Conditions:
Squamous Cell Carcinoma of Head and Neck
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose...
Detailed Description
Head and neck cancer is the eighth most common cancer in the United States . For locally advanced HNSCC, concurrent chemoradiotherapy (chemo-RT) is the standard treatment established with multiple ran...
Eligibility Criteria
Inclusion
- pathologically confirmed squmous cell carcinoma performance status 0-1 adequte renal and hepatic function
Exclusion
- poor performance status
- impaired renal or hepatic function
- =Squamous cell carcinoma of salivary gland,parotid and paranasal carcinomas were --0excluded from the study
- patients with ≥ grade 2 pre-existing peripheral neuropathy, history of allergic reactions to the chemotherapeutic agents, and uncontrolled intercurrent diseases as well as HIV positive patients.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04780750
Start Date
April 1 2021
End Date
September 1 2022
Last Update
March 3 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.